Product Review: Ocrelizumab [Ocrevus®]

In this review: 

This review summarises important pharmacological and clinical characteristics of ocrelizumab [Ocrevus®],
a humanised monoclonal antibody that selectively depletes CD20+ B cells and has demonstrated efficacy in
patients with multiple sclerosis (MS).1-4 Ocrelizumab was registered for use in New Zealand in December 2017
for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) to suppress relapses and
disease progression (clinical and subclinical disease activity).5 Ocrelizumab is also indicated for the treatment
of adult patients with primary progressive multiple sclerosis (PPMS) to delay disease progression and reduce
deterioration in walking speed.

Download PDF Subscribe